Follicular Lymphoma
News
Health Canada expands approval of obinutuzumab
Health Canada has expanded the approved use of obinutuzumab (Gazyva®). The anti-CD20 monoclonal antibody is now approved for use in combination...
News
Transplant strategy not viable for aggressive B-NHL
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-...
News
CHMP recommends CAR T for DLBCL, PMBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the chimeric antigen receptor (...
Conference Coverage
Doc reports favorable results from trial on hold
STOCKHOLM—Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory...
Conference Coverage
Inhibitor exhibits activity in B- and T-cell NHLs
STOCKHOLM—The dual SYK/JAK inhibitor cerdulatinib has demonstrated efficacy in a phase 2 trial of patients with heavily pretreated B- and T-cell...
Conference Coverage
DLBCL survival improved with novel antibody-drug conjugate
Big survival gains were reported in patients with relapsed/refractory DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab.
News
‘Excellent’ survival with HCT despite early treatment failure in FL
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL)...
Conference Coverage
Chemo-free combo provides potential first-line option for FL
CHICAGO—A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus...
Conference Coverage
Polatuzumab plus BR improves efficacy in DLBCL
CHICAGO—Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of...
Conference Coverage
Chemo-free regimen appears viable in previously untreated FL
CHICAGO – Could lenalidomide plus rituximab be a first-line option?